

## Pluvia Biotech welcomes new investors supporting final steps for PKU therapy candidate towards clinical development

Bergen, Norway, 19 May 2026 – Pluvia Biotech, a biotechnology company developing novel therapies for phenylketonuria (PKU), today announced that Mid Atlantic Bio Angels (BioAngels) and Tidligfasekapital Vestland are investing in Pluvia's drug development program. These new investors from the United States and Norway are joining a seed-extension round by Pluvia's existing investors, Sarsia and Investinor, to support final preclinical development steps towards First-in-Human studies for Pluvia's therapeutic candidate PBAS499. This follows the recently announced investment from the US PKU patient advocacy organization, the NPKUA.

Pluvia's lead product PBAS499 was selected to restore endogenous phenylalanine hydroxylase (PAH) activity by stabilizing misfolded PAH variants associated with PKU and enhancing their functional performance. As a pharmacological chaperone, it addresses the underlying cause of the disorder and is being developed as an oral disease-modifying therapy. Through allosteric binding to the PAH enzyme, PBAS499 may offer a differentiated mechanism compared with existing therapies and dietary management approaches, while also providing potential flexibility for use in combination treatment strategies. The addition of BioAngels and Tidligfasekapital strengthen Pluvia's investor base, as the company is completing preclinical activities to progress PBAS499 towards an Investigational New Drug (IND) application for clinical Phase 1/2 studies in healthy volunteers and PKU patients.

"After significant due diligence by our membership base of experienced life science and pharmaceutical professionals, we are pleased to support Pluvia as it advances toward clinical development with the goal of bringing a meaningful new treatment option to PKU patients", says Yaniv Sneor, Founder of Mid Atlantic Bio Angels.

Espen Hundsnes Grøvlén, Fund Manager of Tidligfasekapital Vestland adds "Pluvia is an excellent example of how world-class research originating from Western Norway can be translated into innovative companies with global potential. We are pleased to support Pluvia in this important phase of the company".

Pluvia's CEO Willem van Weperen concludes "The Pluvia team looks forward to working with US and Norwegian investors, alongside patient advocacy organizations, to execute our plans for PBAS499 as a differentiated oral therapy for PKU patients."

### About PKU

PKU, also known as Følling's disease (named after the Norwegian physician Ivar Asbjørn Følling, the first to identify the disease in 1934), is a rare genetic disorder characterized by the body's inability to break down the amino acid phenylalanine (Phe) due to a deficiency in the enzyme PAH, caused by genetic variants. This results in the accumulation of Phe in the bloodstream, leading to intellectual disabilities and other neurological problems if left untreated. Patients need to follow a strict lifelong diet low in Phe, which is found in most protein sources, to prevent cognitive impairment. Convenient oral pharmacological therapy options are needed to help patients to normalize protein intake, while keeping blood phenylalanine levels within recommended ranges.

### About Pluvia Biotech

Pluvia Biotech is a spin-out from the University of Bergen (Norway) dedicated to addressing orphan diseases caused by protein misfolding and having a high unmet medical need. The company's lead program is focused on developing a "first in class" oral pharmacological chaperone treatment of PKU. Through pioneering research and development, Pluvia aims to provide PKU patients with an innovative disease modifying and corrective therapy, and the opportunity to live life without the dietary constraints imposed by the condition. Pluvia's progress is supported by investors Sarsia, Investinor, Trond Mohn Foundation and NPKUA.

### About Mid Atlantic Bio Angels (BioAngels)

The Mid Atlantic Bio Angels (BioAngels™) Group is a NY-based life science angel investor group, formed in 2012, that invests exclusively in life science companies, with no geographic limitations ([www.bioangels.net](http://www.bioangels.net)).

### Tidligfasekapital Vestland

Tidligfasekapital Vestland is an early-stage venture fund manager based in Bergen, Norway, currently deploying capital through its first fund, Tidligfasefond Vestland 1. The fund invests in early-stage companies across a variety of industries with ties to Western Norway. ([www.tidligfasekapitalvestland.no](http://www.tidligfasekapitalvestland.no)).

For more information about Pluvia Biotech and its innovative work in PKU treatment development, please visit [www.pluviabiotech.com](http://www.pluviabiotech.com). For media inquiries and additional information, please contact [info@pluviabiotech.com](mailto:info@pluviabiotech.com)